Plus Therapeutics advances Rhenium Obisbemeda

Plus Therapeutics (PSTV) announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D. The ReSPECT-LM single-dose escalation trial assessed the safety, tolerability, and potential efficacy of intrathecally administered Rhenium Obisbemeda in patients with leptomeningeal metastases. Enrollment in Cohort 6 was recently completed). The Cohort 4 dose was determined to be the RP2D; no dose-limiting toxicities were observed at this dose level. One patient at the Cohort 4 dose was observed to have achieved a complete response, as evidenced by the eradication of tumor cells in the cerebrospinal fluid-a key therapeutic endpoint.